Plasmatic Inactive IL-18 Predicts a Worse Overall Survival for Advanced Non-Small-Cell Lung Cancer with Early Metabolic Progression after Immunotherapy Initiation.
Serena Janho Dit HreichOlivier HumbertTanguy Pacé-LoscosRenaud SchiappaThierry JuhelVéronique HofmanVictoria FerrariJonathan BenzaquenPaul HofmanValérie Vouret-CraviariPublished in: Cancers (2024)
Plasmatic levels of inactive IL-18, combined with circulating neutrophil concentrations, can effectively distinguish ICI nonresponding patients with better overall survival (OS), potentially guiding rapid decisions for therapeutic intensification.